<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Drug resistance of leukemic blasts is correlated to event-free survival and might be predicted by <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression of drug resistance-related proteins </plain></SENT>
<SENT sid="1" pm="."><plain><z:chebi fb="0" ids="44185">Methotrexate</z:chebi> (MTX) is an important component in the treatment of childhood <z:hpo ids='HP_0001909'>leukemia</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Mechanisms of MTX resistance include (1) decreased transport via the reduced <z:chebi fb="3" ids="37445">folate</z:chebi> carrier (RFC), (2) altered levels of target enzymes, eg <z:chebi fb="0" ids="23743">dihydrofolate</z:chebi> reductase (DHFR) and thymidylate synthase (TS), (3) decreased ratio of folylpolyglutamate synthetase (FPGS)/folylpolyglutamate hydrolase (FPGH) </plain></SENT>
<SENT sid="3" pm="."><plain>We designed competitive templates for each of these genes to measure <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression by quantitative RT-PCR and normalized the expression to that of beta-actin </plain></SENT>
<SENT sid="4" pm="."><plain>T-lineage <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e>), relatively MTX resistant compared to common/<z:e sem="disease" ids="C1292769" disease_type="Neoplastic Process" abbrv="">preB-ALL</z:e>, displayed higher <z:chebi fb="2" ids="33699">mRNA</z:chebi> levels of DHFR and TS (three- and four-fold higher, respectively; P &lt; 0.001), while FPGS expression was lower (three-fold, P = 0.006) compared to common/<z:e sem="disease" ids="C1292769" disease_type="Neoplastic Process" abbrv="">preB-ALL</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>The ratio of (DHFR x FPGH)/(RFC x FPGS) was more discriminating between <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">T-ALL</z:e> and c/<z:e sem="disease" ids="C1292769" disease_type="Neoplastic Process" abbrv="">preB-ALL</z:e> (eight-fold higher; P &lt; 0.001) than either target independently </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0004808'>Acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) cells, considered MTX resistant, expressed two-fold lower levels of FPGS <z:chebi fb="2" ids="33699">mRNA</z:chebi> compared to c/<z:e sem="disease" ids="C1292769" disease_type="Neoplastic Process" abbrv="">preB-ALL</z:e> (P = 0.04) </plain></SENT>
<SENT sid="7" pm="."><plain>The ratio of FPGH/FPGS was more discriminating between <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> and c/<z:e sem="disease" ids="C1292769" disease_type="Neoplastic Process" abbrv="">preB-ALL</z:e> (four-fold higher; P = 0.001) than either target independently </plain></SENT>
<SENT sid="8" pm="."><plain>For the total group of 79 leukemic samples, <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression of DHFR varied 549-fold and paralleled TS <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression (r = 0.80; P &lt; 0.001) </plain></SENT>
<SENT sid="9" pm="."><plain>Although variations in <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression resembled variations in functional activity, no direct correlations were found for RFC (58-fold variation in <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression), FPGS (95-fold) and FPGH (178-fold) </plain></SENT>
<SENT sid="10" pm="."><plain>In conclusion, differences in <z:chebi fb="2" ids="33699">mRNA</z:chebi> expression of MTX resistance parameters between leukemic subtypes as detected by competitive RT-PCR are in line with known differences in MTX resistance </plain></SENT>
</text></document>